Skip to main content Back to Top
Advertisement

3/27/2020

Carbidopa and Levodopa Extended-Release Tablets

Products Affected - Description

    • Sinemet CR extended release tablet, Merck, 25 mg/100 mg, bottle, 100 count, NDC 00006-3919-68 - discontinued
    • Sinemet CR extended release tablet, Merck, 50 mg/200 mg, bottle, 100 count, NDC 00006-3918-68 - discontinued

Reason for the Shortage

    • Accord has 50 mg/200 mg tablets available. Accord discontinued carbidopa and levodopa 25 mg/100 mg extended-release tablets.
    • Sun Pharma has carbidopa and levodopa extended-release tablets available.
    • Merck will be discontinuing Sinemet CR 50 mg/200 mg tablets around November 2019. The 25 mg/100 mg tablets will be discontinued around February 2020.
    • Mylan has carbidopa and levodopa extended-release tablets available.

Available Products

    • Carbidopa and Levodopa extended release tablet, Accord, 50 mg/200 mg, bottle, 100 count, NDC 16729-0079-01
    • Carbidopa and Levodopa extended release tablet, Accord, 50 mg/200 mg, bottle, 1000 count, NDC 16729-0079-17
    • Carbidopa and Levodopa extended release tablet, Mylan, 25 mg/100 mg, bottle, 100 count, NDC 00378-0088-01
    • Carbidopa and Levodopa extended release tablet, Mylan, 50 mg/200 mg, bottle, 100 count, NDC 00378-0094-01
    • Carbidopa and Levodopa extended release tablet, Mylan Institutional, 25 mg/100 mg, unit-dose blister pack, 100 count, NDC 51079-0978-20
    • Carbidopa and Levodopa extended release tablet, Mylan Institutional, 50 mg/200 mg, unit-dose blister pack, 100 count, NDC 51079-0923-20
    • Carbidopa and Levodopa extended release tablet, Sun Pharma, 25 mg/100 mg, 100 count, NDC 62756-0461-88
    • Carbidopa and Levodopa extended release tablet, Sun Pharma, 50 mg/200 mg, 100 count, NDC 62756-0457-88

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated March 27, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created September 28, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.